143 related articles for article (PubMed ID: 25573293)
1. Α-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells.
Fan X; He L; Meng Y; Li G; Li L; Meng Y
Mol Med Rep; 2015 May; 11(5):3553-8. PubMed ID: 25573293
[TBL] [Abstract][Full Text] [Related]
2. Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.
Meng Y; Liu S; Li J; Meng Y; Zhao X
Int J Nanomedicine; 2012; 7():3133-42. PubMed ID: 22802682
[TBL] [Abstract][Full Text] [Related]
3. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
4. A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.
Meng Y; Lin S; Liu S; Fan X; Li G; Meng Y
PLoS One; 2014; 9(7):e101998. PubMed ID: 25003606
[TBL] [Abstract][Full Text] [Related]
5. The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo.
Fang EF; Zhang CZ; Wong JH; Shen JY; Li CH; Ng TB
Cancer Lett; 2012 Nov; 324(1):66-74. PubMed ID: 22579806
[TBL] [Abstract][Full Text] [Related]
6. Ribosome-inactivating Protein MAP30 Isolated from
Zhou Y; Yang D; Qiang Z; Meng Y; Li R; Fan X; Zhao W; Meng Y
Recent Pat Anticancer Drug Discov; 2024; 19(2):223-232. PubMed ID: 36330636
[TBL] [Abstract][Full Text] [Related]
7. Mono-PEGylation of Alpha-MMC and MAP30 from Momordica charantia L.: Production, Identification and Anti-Tumor Activity.
Sun Y; Sun F; Li J; Wu M; Fan X; Meng Y; Meng Y
Molecules; 2016 Oct; 21(11):. PubMed ID: 27809255
[TBL] [Abstract][Full Text] [Related]
8. Expression of Momordica charantia MAP30 and its antitumor effect on bladder cancer cells.
Hlin H; Zhi-Guo Z; Cong-Hui H; Yan Z; Qing L; Bo J; Hou-Guang H; Jun-Jie Z; Pei-Ying Z
Minerva Urol Nefrol; 2016 Jun; 68(3):275-81. PubMed ID: 25517785
[TBL] [Abstract][Full Text] [Related]
9. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
Chen WW; Zhang HR; Huang ZG; Zhou ZY; Lou QW; Jiang XY; Zhu ZH
Protein Expr Purif; 2021 Sep; 185():105893. PubMed ID: 33933613
[TBL] [Abstract][Full Text] [Related]
10. MAP30 inhibits autophagy through enhancing acetyltransferase p300 and induces apoptosis in acute myeloid leukemia cells.
Qian S; Sun L; Li J; Wu J; Hu G; Han Y; Yu K; Zhang S
Oncol Rep; 2016 Jun; 35(6):3705-13. PubMed ID: 27035419
[TBL] [Abstract][Full Text] [Related]
11. Alpha-momorcharin (α-MMC) exerts effective anti-human breast tumor activities but has a narrow therapeutic window in vivo.
Cao D; Sun Y; Wang L; He Q; Zheng J; Deng F; Deng S; Chang S; Yu X; Li M; Meng Y; Jin J; Shen F
Fitoterapia; 2015 Jan; 100():139-49. PubMed ID: 25447153
[TBL] [Abstract][Full Text] [Related]
12. MAP30 Inhibits Bladder Cancer Cell Migration and Invasion
Zhang S; Shi Z; Pang K; He H; Chen J; Zhang Z; Zhang Q; Hao L; Han C
DNA Cell Biol; 2020 Nov; 39(11):1948-1960. PubMed ID: 33155841
[TBL] [Abstract][Full Text] [Related]
13. Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity.
Lv Q; Yang XZ; Fu LY; Lu YT; Lu YH; Zhao J; Wang FJ
Protein Expr Purif; 2015 Jul; 111():9-17. PubMed ID: 25797209
[TBL] [Abstract][Full Text] [Related]
14. The heparin-binding domain of HB-EGF as an efficient cell-penetrating peptide for drug delivery.
Luo Z; Cao XW; Li C; Wu MD; Yang XZ; Zhao J; Wang FJ
J Pept Sci; 2016 Nov; 22(11-12):689-699. PubMed ID: 27739168
[TBL] [Abstract][Full Text] [Related]
15. Preferential cytotoxicity of the type I ribosome inactivating protein alpha-momorcharin on human nasopharyngeal carcinoma cells under normoxia and hypoxia.
Pan WL; Wong JH; Fang EF; Chan YS; Ng TB; Cheung RC
Biochem Pharmacol; 2014 Jun; 89(3):329-39. PubMed ID: 24637239
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells.
Fan JM; Luo J; Xu J; Zhu S; Zhang Q; Gao DF; Xu YB; Zhang GP
Mol Biotechnol; 2008 May; 39(1):79-86. PubMed ID: 18246454
[TBL] [Abstract][Full Text] [Related]
17. Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.
Fan JM; Zhang Q; Xu J; Zhu S; Ke T; Gao DF; Xu YB
Mol Biol Rep; 2009 Feb; 36(2):381-8. PubMed ID: 18058255
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon.
Lee-Huang S; Huang PL; Chen HC; Huang PL; Bourinbaiar A; Huang HI; Kung HF
Gene; 1995 Aug; 161(2):151-6. PubMed ID: 7665070
[TBL] [Abstract][Full Text] [Related]
19. Antitumor mechanism of MAP30 in bladder cancer T24 cells, and its potential toxic effects in mice.
Shi Z; Pang K; Yang W; Zhou J; Dong B; Zhang Z; Zhao Y; Han C; Hao L
Cell Mol Biol (Noisy-le-grand); 2020 Apr; 66(1):42-48. PubMed ID: 32359382
[TBL] [Abstract][Full Text] [Related]
20. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].
Zhang LL; Ding Q; Zhan JB
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 May; 39(3):264-71. PubMed ID: 20544988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
